1Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscatway, NJ.
2Department of Pharmacy, Hackensack University Medical Center, Hackensack, NJ
3Department of Pharmacy, Saint Peter’s University Hospital, New Brunswick, NJ.
4Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE.
5Department of Pharmacy Practice, School of Pharmacy, University of Connecticut/Hartford Hospital, Hartford, CT.
6Information and Technology Services, University of Nebraska Medical Center, Omaha, NE.
*See also p. 2675.
Current address for Dr. Thomas: Global Health Sciences, The Medicines Company, Parsippany, NJ.
Current address for Dr. Bandali: Medical Affairs, Janssen Scientific Affairs, Raritan, NJ.
Dr. Thomas consulted (attended advisory board meetings for rivaroxaban and Kcentra) and received support for the development of educational presentations (received honorarium for presenting for Rutgers sponsored Continuing Education presentation). Dr. Olsen received support for travel from the Society of Critical Care Medicine and the American College of Clinical Pharmacy. His institution received grant support from the National Institutes of Health. The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]